UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1342-4
Program Prior Authorization/Notification
Medication Zilxi® (minocycline)
P&T Approval Date 12/2020, 12/2021, 12/2022, 1/2024
Effective Date 4/1/2024
1. Background:
Zilxi is FDA approved for the treatment of inflammatory lesions of rosacea in adults. This
formulation of minocycline has not been evaluated in the treatment of infections.
2. Coverage Criteria:
A. Initial Authorization
1. Zilxi will be approved based on the following criterion:
a. Diagnosis of rosacea with inflammatory lesions.
Authorization will be issued for 12 months.
B. Reauthorization
1. Zilxi will be approved for continuation of therapy based on the following criterion:
a. Documentation of a positive clinical response to therapy
Authorization will be issued for 12 months.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Step Therapy and Supply limits may be in place.
4. References:
1. Zilxi [package insert]. Bridgewater, NJ: Vyne Pharmaceuticals Inc; September 2022.
© 2024 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification - Zilxi
Change Control
12/2020 New program
12/2021 Annual review. Updated reference.
12/2022 Annual review. Updated reference.
1/2024 Annual review. No changes.
© 2024 UnitedHealthcare Services, Inc.
2